PDI 44

Drug Profile

PDI 44

Alternative Names: AZ04; PDI44

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator Ache Laboratories
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Dec 2014 PDI 44 is still in Early research phase for Chronic obstructive pulmonary disease in Brazil (Ache's annual report,
  • 31 Dec 2013 Early research in Chronic obstructive pulmonary disease in Brazil (unspecified route) prior to December (Ache's annual report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top